305 related articles for article (PubMed ID: 37638025)
21. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
22. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
23. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.
de Vries-Brilland M; Rioux-Leclercq N; Meylan M; Dauvé J; Passot C; Spirina-Menand E; Flippot R; Fromont G; Gravis G; Geoffrois L; Chevreau C; Rolland F; Blanc E; Lefort F; Ravaud A; Gross-Goupil M; Escudier B; Negrier S; Albiges L
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935564
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment.
Tachibana H; Inakawa T; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Anticancer Res; 2022 Jun; 42(6):3151-3158. PubMed ID: 35641290
[TBL] [Abstract][Full Text] [Related]
26. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
[TBL] [Abstract][Full Text] [Related]
27. Papillary renal cell carcinoma and clear cell renal cell carcinoma: Differentiation of distinct histological types with contrast - enhanced ultrasonography.
Xue LY; Lu Q; Huang BJ; Li Z; Li CX; Wen JX; Wang WP
Eur J Radiol; 2015 Oct; 84(10):1849-56. PubMed ID: 26149528
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma.
Huang J; Huang D; Yan J; Chen T; Gao Y; Xu D; Na R
Cancer Med; 2020 Dec; 9(24):9409-9418. PubMed ID: 33141518
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
30. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis.
Rosiello G; Palumbo C; Knipper S; Pecoraro A; Luzzago S; St-Hilaire PA; Tian Z; Capitanio U; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2021 Feb; 39(2):461-472. PubMed ID: 32253579
[TBL] [Abstract][Full Text] [Related]
31. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
33. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
Zhao H; Leppert JT; Peehl DM
PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chinese Center.
Liu Z; Ge L; Zhao X; Lu M; Aili A; Li Y; Zhu G; Hong P; Tian X; Wang S; Zhang H; Liu C; Ding Z; Zhang S; Ma L
Clin Med Insights Oncol; 2022; 16():11795549221092217. PubMed ID: 35465470
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.
Xu W; Wu Y; Liu W; Anwaier A; Tian X; Su J; Huang H; Wei G; Qu Y; Zhang H; Ye D
Int J Biol Sci; 2022; 18(13):4884-4900. PubMed ID: 35982911
[No Abstract] [Full Text] [Related]
36. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
[TBL] [Abstract][Full Text] [Related]
37. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
39. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
40. Application of diffusion kurtosis tensor MR imaging in characterization of renal cell carcinomas with different pathological types and grades.
Zhu J; Luo X; Gao J; Li S; Li C; Chen M
Cancer Imaging; 2021 Mar; 21(1):30. PubMed ID: 33726862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
